Skip to main content

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on March 19, 2024.

Official answer

by Drugs.com

Elzonris is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) .

Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

BPDCN is a rare and aggressive hematologic cancer characterized by the malignant proliferation of plasmacytoid dendritic cells (pDCs). It typically presents in the bone marrow, peripheral blood and/or skin, and may also involve the lymph nodes and viscera. It often presents as, or can be mistaken for, acute myeloid leukemia, non-Hodgkin’s lymphoma, acute lymphocytic leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia, as well as other malignancies with skin manifestations.

Diagnosis of BPDCN involves identifying cell surface markers, including the key marker CD123 which expressed in a number of hematologic malignancies, including BPDCN. BPDCN is more accurately diagnosed using an immunophenotypic triad of markers that includes CD123, CD4 and CD56.

Previous names for BPDCN include Blastic Natural Killer (NK) Cell Lymphoma and CD4+/CD56+ Hematodermic Neoplasm.

Elzonris is the first approved treatment for BPDCN and the first CD123-targeted therapy.

Read next

What is the strongest chemotherapy drug for breast cancer?

Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers, not just breast cancer. Doxorubicin is also known as “The Red Devil” because it is a clear bright red color. It can cause your urine or other body fluids to turn a reddish color for 1 to 2 days after a dose is given, which is normal and temporary. Continue reading

Is small cell or non-small cell lung cancer worse?

Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading

Is non-small cell lung cancer hereditary?

A hereditary family history of lung cancer is one of the many risk factors for developing non-small cell lung cancer. About 8% of lung cancers are thought to be inherited or linked to gene changes, but smoking and air pollution remain the primary causes of lung cancer. Continue reading

Related medical questions

Drug information

Related support groups